Publications
Publications in 2018
Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection
Abbosh C, Birkbak NJ, Swanton C
Nat Rev Clin Oncol. 2018 Sep;15(9):577-586
15/09/2018
Genomic instability in mutant p53 cancer cells upon entotic engulfment
Mackay HL, Moore D, Hall C, Birkbak NJ, Jamal-Hanjani M, Karim SA, Phatak VM, Piñon L, Morton JP, Swanton C, Le Quesne J, Muller PAJ.
Nat Commun. 2018 Aug 3;9(1):3070.
03/08/2018
Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors
Hynds, R.E., Ben Aissa, A., Gowers, K.H.C., Watkins, T.B.K., Bosshard-Carter, L., Rowan, A.J., Veeriah, S., Wilson, G.A., Quezada, S.A., Swanton, C., TRACERx Consortium, Janes S.M.
Int J Cancer. 2018 Jul 1;143(1):160-166.
01/07/2018
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada
Cancer Cell. 2018 Apr 9;33(4):649-663.e4.
09/04/2018
Publications in 2017
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C, TRACERx Consortium.
Cell. 2017 Nov 30;171(6):1259-1271.e11
30/11/2017
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Seddon, B. Strauss, S. J. Whelan, J. Leahy, M. Woll, P. J. Cowie, F. Rothermundt, C. Wood, Z. Benson, C. Ali, N. Marples, M. Veal, G. J. Jamieson, D. Kuver, K. Tirabosco, R. Forsyth, S. Nash, S. Dehbi, H. M. Beare, S.
Lancet Oncol. 2017 Oct;18(10):1397-1410.
18/10/2017
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study
Phillips, E. H. Nash, S. Adedayo, T. Whelan, C. J. Fontana, M. Mahmood, S. Lachmann, H. J. Gillmore, J. D. Smith, P. Clifton-Hadley, L. Hawkins, P. N. Wechalekar, A. D.
Amyloid. 2017 Oct 6:1-3.
06/10/2017
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R. Davies, A. Ando, K. Klapper, W. Opat, S. Owen, C. Phillips, E. Sangha, R. Schlag, R. Seymour, J. F. Townsend, W. Trneny, M. Wenger, M. Fingerle-Rowson, G. Rufibach, K. Moore, T. Herold, M. Hiddemann, W.
N Engl J Med 2017; 377:1331-1344
05/10/2017
Patient experience and perceived acceptability of whole-body magnetic resonance imaging for staging colorectal and lung cancer compared with current staging scans: a qualitative study
Evans, R. Taylor, S. Janes, S. Halligan, S. Morton, A. Navani, N. Oliver, A. Rockall, A. Teague, J. Miles, A. Streamline trials, investigators
BMJ Open. 2017 Sep 6;7(9):e016391.
06/09/2017
Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: Significance of pre-treatment and post-resection RAS mutations
Gollins S, West N, Myint AS, Sebag-Montefiore D, Saunders M, Susnerwala S, Quirke P, Essapen S, Samuel L, Sizer B, Worlding J, Southward K, Hemmings G, Tinkler-Hundal E, Bottomley D, Taylor M, Chambers P, Lawrie E, Beare S, Lopes A
Br J Cancer. 2017 Aug 31.
31/08/2017
Tracking the Evolution of Non-Small-Cell Lung Cancer
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C. TRACERx Consortium
N Engl J Med. 2017(376):2109-21
27/07/2017
GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas
Seddon B, Strauss S, Whelan J, Leahy MG, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal G, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S
Lancet Oncol. 2017. (in press)
01/07/2017
Changes in circulating biomarkers in patients with advanced biliary tract cancer receiving cediranib or placebo plus cisplatin and gemcitabine in the UK ABC-03 trial
Backen A, Lopes A, Wasan H, Palmer D, Duggan M, Cunningham D, Anthoney A, Corrie P, Madhusudan S, Maraveyas A, Ross P, Justin W, Steward W, Rees C, McNamara M, Beare S, Bridgewater J, Dive C, Valle J
Clin Cancer Res. 2017. (in press)
01/07/2017
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: Results of the UK NCRI R-CHOP-14 versus 21 trial
Gleeson M, Counsell N, Cunningham D, Chadwick N, Lawrie A, Hawkes E, McMillan A, Ardeshna KM, Jack A, Smith P, Mouncey P, Pocock C, Radford J, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D, Hoskin P
Ann Oncol. 2017. (in press)
01/07/2017
Obinutuzumab-Based Induction and Maintenance in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM study
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour J, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W
N Engl J Med. 2017. (in press)
01/07/2017
The impact of cardiac radiation dosimetry on survival following radiotherapy for non-small cell lung cancer
Vivekanandan S, Landau D, Counsell N, Warren D.R, Khwanda A, Rosen S.D, Parsons E, Ngai Y, Farrelly L, Hughes L, Hawkins M.A, Fenwick J.D.
Int J Radiat Oncol Biol Phys. 2017. (in press)
01/07/2017
Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study
Bray TJP, Singh S, Latifoltojar A, Rajesparan K, Rahman F, Narayanan P, Naaseri S, Lopes A, Bainbridge A, Punwani S, Hall-Craggs MA
PLoS One. 2017,12(7):e0180562
01/07/2017
Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Wood G, Grenader T, Nash S, Adams R, Kaplan R, Fisher D, Maughan T, Bridgewater J.
Anticancer Drugs. 2017 Jun;28(5):546-550. doi: 10.1097/CAD.0000000000000488.
01/06/2017
Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer
Read ML, Fong JC, Modasia B, Fletcher A, Imruetaicharoenchoke W, Thompson RJ, Nieto H, Reynolds JJ, Bacon A, Mallick U, Hackshaw A, Watkinson JC, Boelaert K, Turnell AS, Smith VE, McCabe CJ
Oncogene. 2017. May 15. doi: 10.1038/onc.2017.154. [Epub ahead of print]
15/05/2017
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A
J Clin Oncol. 2017;35(14):1506-14
10/05/2017
Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia
Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ
Leukemia. 2017;31(5):1087-109.
01/05/2017
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Quesne JL, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Bakir MA, GrOnroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie P, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJ, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C
Nature. 2017,545(7655):446-451.
26/04/2017
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA
Immunity. 2017 Apr 18;46(4):577-586.
18/04/2017
Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
Kuhnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D
Ann Oncol. 2017 Apr 7. [ahead of print]
07/04/2017
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET)
Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer JM, Ferry D, Lewanski C, Forster M, Rolls SA, Capitanio A, Rudd R, Iles N, Ngai Y, Gandy M, Lillywhite R, Hackshaw A
J Clin Oncol. 2017;35(4):402-11
01/04/2017
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial
Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, Benstead K, Harte RJ, Stewart J, Beare S, Hackshaw A, Kadalayil L
Lancet Oncol. 2017,18(3):347-56
01/04/2017
Clinical Endpoints in Clinical Trials of Chemoradiation for Anal Cancer
Glynne-Jones R, Meadows H, Lopes A, Adams R
Lancet Oncol. 2017 Apr;18(4):e218-e227. doi: 10.1016/S1470-2045(17)30190-0.
01/04/2017
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA, Melanoma TC, Renal TC, Lung TC, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA
Immunity. 2017,46(4):577-86
01/04/2017
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
Wheeler GM, Sweeting MJ, Mander AP
Stat Med. 2017 Mar 15. doi: 10.1002/sim.7280. [Epub ahead of print]
15/03/2017
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial
Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, Benstead K, Harte RJ, Stewart J, Beare S, Hackshaw A, Kadalayil L; ACT II study group
Lancet Oncol. 2017 Mar;18(3):347-356. doi: 10.1016/S1470-2045(17)30071-2. Epub 2017 Feb 11
01/03/2017
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemoine N, Sheaff MT, Rudd RM, Fennell D, Hackshaw A
JAMA Oncol. 2017;3(1):58-66
01/03/2017
Investigating Subgroup Effects in Randomized Clinical Trials
Dehbi HM, Hackshaw A
J Clin Oncol. 2017,35(2):253-4
01/02/2017
Publishing interim results of randomised clinical trials in peer-reviewed journals
Counsell N, Biri D, Fraczek J, Hackshaw A
Clin Trials. 2017,14(1):67-77
01/01/2017
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups
Shankar AG, Roques G, Kirkwood AA, Lambilliotte A, Freund K, Leblanc T, Hayward J, Abbou S, Ramsay AD, Schmitt C, Gorde-Grosjean S, Pacquement H, Haouy S, Boudjemaa S, Aladjidi N, Hall GW, Landman-Parker J
Br J Haematol. 2017
01/01/2017
Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L)
Taylor SA, Mallett S, Miles A, Beare S, Bhatnagar G, Bridgewater J, et al
BMC cancer. 2017;17(1):299.
01/01/2017
Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials
Raine R, Atkin W, von Wagner C, Duffy S, Kralj-Hans I, Hackshaw A, Counsell N, Moss S, McGregor L, Palmer C, Smith SG, Thomas M, Howe R, Vart G, Band R, Halloran SP, Snowball J, Stubbs N, Handley G, Logan R, Rainbow S, Obichere A, Smith S, Morris S, Solmi F, Wardle J
Programme Grants for Applied Research; NIHR Journals Library. Southampton (UK) 2017.
01/01/2017
Dose specification for hippocampal sparing whole brain radiotherapy (HS WBRT): considerations from the UK HIPPO trial QA programme
Megias D, Phillips M, Clifton-Hadley L, Harron E, Eaton DJ, Sanghera P, Whitfield G
Br J Radiol. 2017;90(1071):20160829
01/01/2017
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials
McNamara MG, Bridgewater J, Lopes A, Wasan H, Malka D, Jensen LH, Okusaka T, Knox JJ, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, Valle JW
BMC Cancer. 2017;17(1):262
01/01/2017
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review
Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, MacDonald N, Ledermann JA
Gynecol Oncol. 2017;144(1):57-60.
01/01/2017
Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches
Lanceley A, Berzuini C, Burnell M, Gessler S, Morris S, Ryan A, Ledermann JA, Jacobs I
Int J Gynecol Cancer. 2017;27(1):59-68
01/01/2017
Improving uptake of flexible sigmoidoscopy screening: a randomized trial of nonparticipant reminders in the English Screening Programme
Kerrison RS, McGregor LM, Marshall S, Isitt J, Counsell N, Rees CJ, von Wagner C
Endoscopy. 2017;49(1):35-43
01/01/2017
Text-message Reminders in Colorectal Cancer Screening (TRICCS): a randomised controlled trial
Hirst Y, Skrobanski H, Kerrison RS, Kobayashi LC, Counsell N, Djedovic N, Ruwende J, Stewart M, von Wagner C
Br J Cancer. 2017,116(11):1408-14
01/01/2017
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)
Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, Anderson JR, Judson I, Litiere S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G
Pediatr Blood Cancer. 2017,64(8)
01/01/2017
Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards
Dehbi HM, Royston P, Hackshaw A
BMJ. 2017,357:j2250
01/01/2017
Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial
Ahern AL, Wheeler GM, Aveyard P, Boyland EJ, Halford JCG, Mander AP, Woolston J, Thomson AM, Tsiountsioura M, Cole D, Mead BR, Irvine L, Turner D, Suhrcke M, Pimpin L, Retat L, Jaccard A, Webber L, Cohn SR, Jebb SA
Lancet. 2017,389(10085):2214-25
01/01/2017
Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bennett A, Chow CK, Chou M, Dehbi HM, Webster R, Salam A, Patel A, Neal B, Peiris D, Thakkar J, Chalmers J, Nelson M, Reid C, Hillis GS, Woodward M, Hilmer S, Usherwood T, Thom S, Rodgers A
Hypertension. 2017,70(1):85-93
01/01/2017
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
Patel B, Kirkwood AA, Dey A, Marks DI, McMillan AK, Menne TF, Micklewright L, Patrick P, Purnell S, Rowntree CJ, Smith P, Fielding AK
Leukemia. 2017;31(1):58-64.
01/01/2017
Publications in 2016
A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening
Raine R, Moss SM, von Wagner C, Atkin W, Hans IK, Howe R, Solmi F, Morris S, Counsell N, Hackshaw A, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Seaman H, Thomas M, Smith SG, McGregor LM, Vart G, Wardle J, Duffy SW
Br J Cancer. 2016,115(12):1479-86
01/12/2016
Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK
Khoja L, Nolan K, Mekki R, Milani A, Mescallado N, Ashcroft L, Hasan J, Edmondson R, Winter-Roach B, Kitchener HC, Mould T, Hutson R, Hall G, Clamp AR, Perren T, Ledermann J, Jayson GC
Clin Oncol (R Coll Radiol). 2016,28(12):760-5.
01/12/2016
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
UK CLL Forum
Haematologica. 2016 Dec;101(12):1563-1572
01/12/2016
Study protocol for a randomised controlled trial of brief, habit-based, lifestyle advice for cancer survivors: exploring behavioural outcomes for the Advancing Survivorship Cancer Outcomes Trial (ASCOT)
Beeken RJ, Croker H, Heinrich M, Smith L, Williams K, Hackshaw A, Hines J, Machesney M, Krishnaswamy M, Cavanagh S, Roylance R, Hill A, Pritchard-Jones K, Wardle J, Fisher A
BMJ Open. 2016,6(11):e011646
01/11/2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
Ledermann JAH, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., Matei, D., Fielding, A., Bennett, B., Parry, D., Spencer, S., Mann, H., Matulonis, U
Br J Cancer. 2016,115(11):1313-20
01/11/2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U
Lancet Oncol. 2016,17(11):1579-89
01/11/2016
A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials
Wheeler GM, Sweeting MJ, Mander AP
PLoS One. 2016,11(7):e0159026
01/11/2016
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis
De Ruysscher D, Lueza B, Le Pechoux C, Johnson DH, O'Brien M, Murray N, Spiro S, Wang X, Takada M, Lebeau B, Blackstock W, Skarlos D, Baas P, Choy H, Price A, Seymour L, Arriagada R, Pignon JP, RTT-SCLC Collaborative Group
Ann Oncol. 2016,27(10):1818-28
01/10/2016
Quality of life, long-term survivors and long-term outcome from the ABC-02 study
Bridgewater J, Lopes A, Palmer D, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Valle J, Wasan H
Br J Cancer. 2016,114(9):965-71
01/09/2016
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320
Townsend W, Johnson RJ, Pottinger BT, Counsell N, Smith P, Chadwick H, Evans K, Wickham C, Rudin CE, Group UNLCS
Leuk Lymphoma. 2016,57(9):2232-4
01/09/2016
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations
Miller RE, Ledermann JA
Clin Adv Hematol Oncol. 2016,14(9):704-11
01/09/2016
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL, Portec study group
Lancet Oncol. 2016,17(8):1114-26
17/08/2016
Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin
Watkins RJ, Imruetaicharoenchoke W, Read ML, Sharma N, Poole VL, Gentilin E, Bansal S, Bosseboeuf E, Fletcher R, Nieto HR, Mallick U, Hackshaw A, Mehanna H, Boelaert K, Smith VE, McCabe CJ
J Clin Endocr Metab. 2016,101(12):4551-63
01/08/2016
Use of a 12 months' self-referral reminder to facilitate uptake of bowel scope (flexible sigmoidoscopy) screening in previous non-responders: a London-based feasibility study
Kerrison RS, McGregor LM, Marshall S, Isitt J, Counsell N, Wardle J, von Wagner C
Br J Cancer. 2016,114(7):751-8
01/07/2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S
N Engl J Med. 2016,374(25):2419-29
23/06/2016
IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer
Landau DB, Hughes L, Baker A, Bates AT, Bayne MC, Counsell N, Garcia-Alonso A, Harden SV, Hicks JD, Hughes SR, Illsley MC, Khan I, Laurence V, Malik Z, Mayles H, Mayles WP, Miles E, Mohammed N, Ngai Y, Parsons E, Spicer J, Wells P, Wilkinson D, Fenwick JD
Int J Radiat Oncol Biol Phys. 2016,95(5):1367-77
01/05/2016
Improving target volume delineation in intact cervical carcinoma: Literature review and step-by-step pictorial atlas to aid contouring
Eminowicz G, Hall-Craggs M, Diez P, McCormack M
Pract Radiat Oncol. 2016,6(5):e203-13.
01/05/2016
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
Brown N, McBain C, Nash S, Hopkins K, Sanghera P, Saran F, Phillips M, Dungey F, Clifton-Hadley L, Wanek K, Krell D, Jeffries S, Khan I, Smith P, Mulholland P
PLoS One. 2016,11(5):e0156369
01/05/2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial
Gleeson M, Hawkes EA, Cunningham D, Chadwick N, Counsell N, Lawrie A, Jack A, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Linch D
Br J Haematol. 2016,175(4):668-72
01/04/2016
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fossa A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW
Blood. 2016,127(12):1531-8
24/03/2016
The dosimetric impact of target volume delineation variation for cervical cancer radiotherapy
Eminowicz G, Rompokos V, Stacey C, McCormack M
Radiother Oncol. 2016,120(3):493-9
01/03/2016
Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours
Childs A, Kirkwood A, Edeline J, Luong TV, Watkins J, Lamarca A, Alrifai D, Nsiah-Sarbeng P, Gillmore R, Mayer A, Thirlwell C, Sarker D, Valle JW, Meyer T
Endocr Relat Cancer. 2016,23(7):563-70
01/03/2016
Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening
Raine R, Duffy SW, Wardle J, Solmi F, Morris S, Howe R, Kralj-Hans I, Snowball J, Counsell N, Moss S, Hackshaw A, von Wagner C, Vart G, McGregor LM, Smith SG, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Atkin W
Br J Cancer. 2016,114(3):321-6.
01/03/2016
Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group
Shankar AG, Kirkwood AA, Depani S, Bianchi E, Hayward J, Ramsay AD, Hall GW
Br J Haematol. 2016,173(3):421-31
01/03/2016
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA
J Thorac Oncol. 2016,11(3):312-23
01/03/2016
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial
Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D
Haematologica. 2016,101(2):235-40.
01/02/2016
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D.
Haematologica. 2016 Feb;101(2):235-40. doi: 10.3324/haematol.2015.128710. Epub 2015 Nov 26.
01/02/2016
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.
Int J Gynecol Cancer. 2016 Jan;26(1):2-30. doi: 10.1097/IGC.0000000000000609.
01/01/2016
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up†.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.
Ann Oncol. 2016 Jan;27(1):16-41. doi: 10.1093/annonc/mdv484. Epub 2015 Dec 2.
01/01/2016
PET-CT for staging & early response: results from 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) (CRUK/07/033).
Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fosså A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW.
Blood. 2016 Jan 8. pii: blood-2015-11-679407. [Epub ahead of print]
01/01/2016
Reducing the Social Gradient in Uptake of the NHS Colorectal Cancer Screening Programme Using a Narrative-Based Information Leaflet: A Cluster-Randomised Trial
McGregor LM, von Wagner C, Atkin W, Kralj-Hans I, Halloran SP, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Thomas MC, Smith SG, Vart G, Howe R, Counsell N, Hackshaw A, Morris S, Duffy SW, Raine R, Wardle J
Gastroent Res Pract. 2016
01/01/2016
Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer
Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N, Olaitan A, Mould T, Meyer T, Hartley J, Mitra A, Ledermann JA, McCormack M, Kristeleit RS
Oncology. 2016,91(1):48-54
01/01/2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJ, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, Gonzalez-Martin A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MK, ICON6 collaborators.
Lancet. 2016,387(10023):1066-74.
01/01/2016
Research in progress-LungSEARCH: a randomised controlled trial of surveillance for the early detection of lung cancer in a high-risk group
Spiro SG, Hackshaw A, on behalf of the LungSEARCH Collaborative Group
Thorax. 2016,71(1):91-3.
01/01/2016
Incoherent dose-escalation in phase I trials using the Escalation with Overdose Control approach
Wheeler GM
Statistical Papers. 2016; 1-11. doi:10.1007/s00362-016-0790-7
01/01/2016
Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials
Wardle J, von Wagner C, Kralj-Hans I, Halloran SP, Smith SG, McGregor LM, Vart G, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Counsell N, Morris S, Duffy SW, Hackshaw A, Moss S, Atkin W, Raine R
Lancet. 2016,387(10020):751-9
01/01/2016
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, McEntee D, Sukumaran A, Wasan H, Valle JW
BMC Cancer. 2016,16:153
01/01/2016
Prognostic factors for progression-free and overall survival in advanced biliary tract cancer
Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, et al
Ann Oncol. 2016,27(1):134-40
01/01/2016
Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit
King JP, D.H., Johnson, P., Ross, P., Hubner, R.A., Sumpter, K., Darby, S., Braconi, C., Iwuji, C., Swinson, D., Collins, P., Patel, K., Nobes, J., Muazzam, I., Blesing, C., Kirkwood, A., Nash, S., Meyer, T
Clinical Oncology. 2016
01/01/2016
Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms
Khan MS, Kirkwood AA, Tsigani, T., Lowe, H., Goldstein, R., Hartley, J.A., Caplin, M.E., Meyer, T
Clinical Cancer Research. 2016,22(1):79-85
01/01/2016
Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial
Jenkinson S, Kirkwood AA, Goulden N, Vora A, Linch DC, Gale RE
Leukemia. 2016,30(1):39-47
01/01/2016
Text Reminders in Colorectal Cancer Screening (TRICCS): Protocol for a randomised controlled trial
62. Hirst Y, Kerrison R, Kobayashi LC, Counsell N, Djedovic N, Ruwende J, Stewart M, von Wagner C
BMC Public Health. 2016,16:74
01/01/2016
Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol
Heinrich M, Fisher A, Paton B, McCourt O, Beeken RJ, Hackshaw A, Wardle J, Yong K
BMC Cancer. 2016,16:387
01/01/2016
Publications in 2015
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO–ESGO–ESTRO Endometrial Consensus Conference Working Group.
Radiother Oncol. 2015 Dec;117(3):559-81. doi: 10.1016/j.radonc.2015.11.013. Epub 2015 Dec 9.
01/12/2015
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
Ledermann JA, El-Khouly F.
Br J Cancer. 2015 Dec 15;113 Suppl 1:S10-6. doi: 10.1038/bjc.2015.395.
01/12/2015
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum
Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M, Bacchus investigators
BMC Cancer. 2015,15:764
23/10/2015
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.
Ledermann JA, Canevari S, Thigpen T.
Ann Oncol. 2015 Oct;26(10):2034-43. doi: 10.1093/annonc/mdv250. Epub 2015 Jun 10.
01/10/2015
A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A, Stratford M, Jitlal M, Hackshaw A.
J Natl Cancer Inst. 2015 Aug 4;107(10). pii: djv197. doi: 10.1093/jnci/djv197. Print 2015 Oct.
01/10/2015
Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: ABC-02 and BT-22 studies
Grenader T, Nash S, Plotkin Y, Furuse J, Mizuno N, Okusaka T, Wasan H, Valle J, Bridgewater J
Ann Oncol. 2015,26(9):1910-6
26/09/2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015.
du Bois A, Reuss A, Pujade-Lauraine E, Pignata S, Ledermann J, Casado A, Sehouli J, Mirza M, Colombo N, Marth C, Witteveen E, Del Campo J, Calvert P, Aravantinos G, Vardar MA, van der Zee AG, Korach J, Taskiran C, Fehr M, Glasspool R, Pfisterer J, Cibula D, Vergote I; member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT).
Int J Gynecol Cancer. 2015 Sep;25(7):1328-30. doi: 10.1097/IGC.0000000000000478.
01/09/2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA
Lancet Oncol. 2015,16(8):967-78.
16/08/2015
A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer
Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A, Stratford M, Jitlal M, Hackshaw A
J Natl Cancer Inst. 2015,107(10): djv197.
04/08/2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.
Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.
01/08/2015
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).
McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X, Mikami Y, Stewart CJ, Vang R, Hirschowitz L.
Mod Pathol. 2015 Aug;28(8):1101-22. doi: 10.1038/modpathol.2015.77. Epub 2015 Jun 19.
01/08/2015
The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership.
Marth C, du Bois A, Schauer C, du Bois A, Casado A, Vergote I, del Campo JM, Goudopoulou A, Pujade-Lauraine E, Bruchim I, Colombo N, Pignata S, Ledermann J, Chekerov R, Raza Mirza M, Westermann A, Glasspool R, Taskiran C, Fehr M, Cibula D.
Int J Gynecol Cancer. 2015 Jul;25(6):1094-5. doi: 10.1097/IGC.0000000000000446.
01/07/2015
An overview of early investigational therapies for chemoresistant ovarian cancer.
Marchetti C, Ledermann JA, Benedetti Panici P.
Expert Opin Investig Drugs. 2015;24(9):1163-83. doi: 10.1517/13543784.2015.1072168. Epub 2015 Jul 24.
01/07/2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA
Lancet Oncol. 2015 Jul 10. pii: S1470-2045(15)00139-4. doi: 10.1016/S1470-2045(15)00139-4. [Epub ahead of print]
01/07/2015
Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
Khan I, Morris S, Hackshaw A, Lee SM
BMJ Open. 2015,5(7):e006733
01/07/2015
Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - A review of clinical outcome based on the histological variants
Shankar AG, Kirkwood AA, Hall GW, Hayward J, O'Hare P, Ramsay A
Br J Haematol. 2015
26/06/2015
The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma
Venturelli S, Dalla Pria A, Stegmann K, Smith P, Bower M
Br J Cancer. 2015,113(6):861-3
01/06/2015
Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.
Matulonis UA, Oza AM, Ho TW, Ledermann JA.
Cancer. 2015 Jun 1;121(11):1737-46. doi: 10.1002/cncr.29082.
01/06/2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma
Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S
N Engl J Med. 2015,372(17):1598-607
23/04/2015
Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J, Harter P, Gourley C.
Lancet Oncol. 2015 Apr;16(4):e158. doi: 10.1016/S1470-2045(15)70153-1.
01/04/2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma
Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S.
N Engl J Med. 2015 Apr 23;372(17):1598-607. doi: 10.1056/NEJMoa1408648.
01/04/2015
Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control
Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EY, Dowson S, Webber L, Khan I, Ennis D, Syed N, Crook TR, Brenton JD, Lockley M, McNeish IA
Mol Oncol. 2015 Apr;9(4):791-805
01/04/2015
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer
Gurung PM, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ, Short SC, Freeman A, Powles T, Hoskin PJ, West CM, Kelly JD
Int J Cancer. 2015,136(3):709-20
01/03/2015
Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data
Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, Glynne-Jones R, Counsell N, Bastiaannet E, van den Broek CB, Liefers GJ, Putter H, van de Velde CJ
Lancet Oncol. 2015,16(2):200-7
01/02/2015
New clinical research strategies for rare gynecologic malignancies.
Ray-Coquard I, Pujade-Lauraine E, Ledermann JA.
Curr Opin Obstet Gynecol. 2015 Feb;27(1):53-7. doi: 10.1097/GCO.0000000000000144.
01/02/2015
Planning an Academic Clinical Trial.
Champion KM, Jones GR.
Methods Mol Biol. 2015;1317:287-313. doi: 10.1007/978-1-4939-2727-2_16.
01/01/2015
Do Cell-Cycle Phase-Specific Markers Predict Disease Grade, Stage, and Outcome in Cervical Carcinoma?
Kuku S, Proctor I, Loddo M, Kadalayil L, KhoshZaban M, McCormack M, Ledermann J.
Int J Gynecol Cancer. 2015 Jan 23. [Epub ahead of print]
01/01/2015
A Phase II Study to Determine the Efficacy and Safety of Oral Treosulfan in Patients With Advanced Pre-Treated Ewing Sarcoma ISRCTN11631773
Michelagnoli M, Whelan J, Forsyth S on behalf of the OTIS Trial Management Group, Site Investigators
Pediatr Blood Cancer 2015;62:158–159
01/01/2015
Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)
Okasha D, Kirkwood A, Copland M, Lawrie E, McMillan A, Menne TF, Morley N, Rowntree C, Richardson DS, Smith P, Fielding AK, Marks D
Blood. 2015,126(23):733
01/01/2015
Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease
Lamarca A, Benafif S, Ross P, Bridgewater J, Valle JW
Eur J Cancer. 2015,51(13):1694-703
01/01/2015
Publications in 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix.
Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, Pautier P, Reed NS, Fujiwara K.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S102-8. doi: 10.1097/IGC.0000000000000262.
01/11/2014
International Journal of Gynecological Cancer. Editorial.
Ray-Coquard I, Ledermann J.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S2-4. doi: 10.1097/IGC.0000000000000234.
01/11/2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.
Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-7. doi: 10.1097/IGC.0000000000000249.
01/11/2014
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzanzanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S20-5. doi: 10.1097/IGC.0000000000000289.
01/11/2014
Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma
Ledermann JA, Luvero D, Shafer A, O'Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J, Oza A, Brown J
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S14-9. doi: 10.1097/IGC.0000000000000296.
01/11/2014
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M, Hall G, Clamp A, Earl H, Banerjee S, Kristeleit R, Raja F, Feeney A, Lawrence C, Dawson-Athey L, Persic M, Khan I.
Ann Oncol. 2014 Oct;25(10):1988-95. doi: 10.1093/annonc/mdu363. Epub 2014 Jul 28.
01/10/2014
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
McNeish I, Ledermann J, Webber L, James L, Kaye S, Hall M, Hall G, Clamp A, Earl H, Banerjee S, Kristeleit R, Raja F, Feeney A, Lawrence C, Dawson-Athey L, Persic M, Khan I.
Ann Oncol. 2014 Oct;25(10):1988-95. doi: 10.1093/annonc/mdu363.
01/10/2014
Maintenance therapy in ovarian cancer
Khalique S, Hook JM, Ledermann JA
Curr Opin Oncol. 2014 Sep;26(5):521-8. doi: 10.1097/CCO.0000000000000110.
01/09/2014
ACT II Study Group. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II tria
Glynne-Jones R, Kadalayil L, Meadows HM, Cunningham D, Samuel L, Geh JI, Lowdell C, James R, Beare S, Begum R, Ledermann JA, Sebag-Montefiore D
Ann Oncol. 2014 Aug;25(8):1616-22. doi: 10.1093/annonc/mdu188. Epub 2014 May 14.
01/08/2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A,Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U
Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31.
01/07/2014
Chronicle: Results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (Xelox) versus control
Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, Ledermann J, Sebag-Montefiore D
Ann Oncol. 2014 Jul;25(7):1356-62. doi: 10.1093/annonc/mdu147. Epub 2014 Apr 8.
01/07/2014
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study
Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornas
PLoS Biol. 2014 Jul 8;12(7):e1001906. doi: 10.1371/journal.pbio.1001906
01/07/2014
Optimal treatment of early-stage ovarian cancer
Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, Ledermann J, Colombo N, Swart A; ICON1 collaborators
Ann Oncol. 2014 Jun;25(6):1165-71. doi: 10.1093/annonc/mdu116. Epub 2014 Mar 14.
01/06/2014
Impact of diabetes mellitus and renal insufficiency on 5-year mortality following coronary artery bypass graft surgery: a cohort study of 4869 UK patients
Gallagher S, Kapur A, Lovell MJ, Jones DA, Kirkwood A, Hassan S, Archbold RA, Wragg A, Uppal R, Yaqoob MM
Eur J Cardiothorac Surg. 2014,45(6):1075-81
01/06/2014
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma – results of the UK HD3 relapse treatment strategy
Shankar A, Haywood J, Kirkwood A, McCarthy K, Hewitt M, Morland B, Daw S
Br J Haematol. 2014,165(4):534–44
01/05/2014
Tumour- and treatment-related colostomy rates following Mitomycin or Cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial
Glynne-Jones R, Kadalayil L, Meadows HM, Cunningham D, Samuel L, Geh JI, Lowdell C, James R, Beare S, Begum R, Ledermann JA, Sebag-Montefiore D; on behalf of the ACT II study group
Ann Oncol. 2014 May 14. pii: mdu188. [Epub ahead of print]
01/05/2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
Ardeshna KMQ, W., Smith, P., Braganca, N., Lowry, L., Patrick, P., Warden, J., Stevens, L., Pocock, C.F., Miall, F., Cunningham, D., Davies, J., Jack, A., Stephens, R., Walewski, J., Ferhanoglu, B., Bradstock, K., Linch, D.C
Lancet Oncol. 2014,15(4):424-35
15/04/2014
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial
Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, Coltart S, Illidge T, Madhavan K, Brammer C, Diez P, Jack A, Syndikus I
Lancet Oncol. 2014,15(4):457-63
15/04/2014
Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges.
Ledermann JA, Ray-Coquard I.
Am Soc Clin Oncol Educ Book. 2014:e282-6. doi: 10.14694/EdBook_AM.2014.34.e282.
01/04/2014
End points in anal cancer: hopes for a common language
Glynne-Jones R, Adams RA, Jitlal M, Meadows H
J Clin Oncol. 2014 Apr 20;32(12):1281-2
01/04/2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC
Lancet Oncol. 2014 Apr;15(4):424-35.
01/04/2014
Better therapeutic trials in ovarian cancer
Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD.
J Natl Cancer Inst. 2014 Apr;106(4)
01/04/2014
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial
Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, Coltart S, Illidge T, Madhavan K, Brammer C, Diez P, Jack A, Syndikus I
Lancet Oncol. 2014 Apr;15(4):457-63.
01/04/2014
Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983
Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T, Schlag PM, Punt CJ, Ledermann J, Ruers TJ.
Eur J Cancer. 2014 Mar;50(5):912-9.
01/03/2014
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J, Okusaka T.
Ann Oncol. 2014 Feb;25(2):391-8
01/02/2014
Biomarkers and response to bevacizumab--response
Collinson F, Hutchinson M, Craven RA, Cairns DA, Alexandre Z, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann J, Hall G,Jayson GC, Selby PJ, Banks RE
Clin Cancer Res. 2014 Feb 15;20(4):1058. doi: 10.1158/1078-0432.CCR-13-3269.
01/02/2014
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial
Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, Jack A, El-Mehidi N, Johnson PW, Radford J, Linch DC, Cunnningham D.
J Clin Oncol. 2014 Feb 1;32(4):282-7
01/02/2014
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases
Lee SM, Lewanski CR, Counsell N, Ottensmeier C, Bates A, Patel N, Wadsworth C, Ngai Y, Hackshaw A, Faivre-Finn C
J Natl Cancer Inst. 2014 Jul 16;106(7). pii: dju151. doi: 10.1093/jnci/dju151. Print 2014 Jul.
01/01/2014
Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges
Ledermann JA, Ray-Coquard I
Am Soc Clin Oncol Educ Book. 2014:e282-6. doi: 10.14694/EdBook_AM.2014.34.e282.
01/01/2014
A non-linear Beta-Binomial regression model for mapping QLQC-30 to the EQ-5D in lung cancer patients: A comparison with existing approaches
I Khan, S Morris
Quality of Life Research 2014 (in press)
01/01/2014
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee JM, Ledermann JA, Kohn EC.
Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384.
01/01/2014
SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status
Maguire J, Khan I, McMenemin R, O'Rourke N, McNee S, Kelly V, Peedell C, Snee M
Eur J Cancer. 2014,50(17):2939-49
01/01/2014
Improving research on the efficacy, effectiveness, and harms of traditional chinese medicine
Tang JL, Hackshaw A, Lao LX, Liu BY, Chung VC
Evid Based Complement Alternat Med. 2014,2014:657679
01/01/2014
Publications in 2013
Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data
Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, Vergote IB, Gonzalez-Martin A, Alberts DS, Plante M, Torri V, Ledermann JA.
Ann Oncol. 2013 Dec;24(12):3028-34
01/12/2013
Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
Illidge T, Chan C, Counsell N, Morris S, Scarisbrick J, Gilson D, Popova B, Patrick P, Smith P, Whittaker S, Cowan R.
Br J Cancer. 2013 Nov 12;109(10):2566-73
01/11/2013
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T.
Ann Oncol. 2013 Oct;24(10):2565-70
01/10/2013
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO Guidelines Working Group
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
01/10/2013
Application of methods for central statistical monitoring in clinical trials
Kirkwood AA, Cox T, Hackshaw A.
Clin Trials. 2013 Oct;10(5):783-806
01/10/2013
A non-linear beta-binomial regression model for mapping qlqc-30 to the eq-5d in lung cancer patients: a comparison with existing approaches
Khan I, Sarker SJ, Morris S
Trials 2013, 14(Suppl 1):O23
01/10/2013
Well-being after radiation therapy in thyroid cancer
Hackshaw A, Kadalayil L, Mallick U
N Engl J Med. 2013,368(7):685-6
01/07/2013
A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework
Sarker SJ, Whitehead A, Khan I.
Comput Methods Programs Biomed. 2013 Jun;110(3):471-89
01/06/2013
PET-CT for staging and early response – results from the Response Adapted Therapy in Advanced Hodgkin Lymphoma (RATHL) study
Sally F Barrington, Michael J O’Doherty, Thomas Roberts, Amy Kirkwood, Zaid Viney, Rebecca Preston, Antonella Franceschetto, Michael Fulham, Marina Cucca, Helen Almquist, Eva Brun, Karin Hjorthaug, Lucy Pike, Donald Sinclair, Peter Johnson.
The 12th International Conference on Malignant Lymphoma, Lugano
01/06/2013
Responses defined by PET-CT imaging: first results from the international Response Adapted Therapy in advanced Hodgkin Lymphoma (RATHL) study.
Johnson, Federico, Fossa, O’Doherty, Roberts, Stevens, Smith, Kirkwood, Berkhan, Trotman, Enblad, D’Amore, Luminari, Viney, Radford, Barrington.
The 12th International Conference on Malignant Lymphoma, Lugano
01/06/2013
A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer
M. McCormack, L. Kadalayil, A. Hackshaw, M. A. Hall-Craggs, R.P. Symonds, V. Warwick, H. Simonds, I. Fernando, M. Hammond, L. James, A. Feeney, J. A. Ledermann
Br J Cancer. 2013 Jun 25;108(12):2464-9
01/06/2013
A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial
Lee SM, Hackshaw A
Cancer Med. 2013 Jun;2(3):360-6.
01/06/2013
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
Lancet. 2013 May 25;381(9880):1817-26
01/05/2013
Exploiting FOXM1-Orchestrated Molecular Network for Early Squamous Cell Carcinoma Diagnosis and Prognosis
Teh MT, Hutchison IL, Costea DE, Neppelberg E, Liavaag PG, Purdie K, Harwood C, Wan H, Odell EW, Hackshaw A, Waseem A
Int J Cancer. 2013 May 1;132(9):2095-106
01/05/2013
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma
Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, Narat S, D’Sa S, Rabin N, Johnston R, Schey S, Yong K
Eur J Haematol. 2013 May;90(5):420-5
01/05/2013
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial
James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D.
Lancet Oncol. 2013 May;14(6):516-24
01/05/2013
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenbergh E, Mackinnon S, Chakraverty R
Br J Haematol. 2013,160(5):640-8
01/05/2013
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma
Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK.
Br J Cancer. 2013 Apr 2;108(6):1252-9
01/04/2013
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy
Lowry L, Smith P, Cunningham D, Linch DC.
J Geriatr Oncol. 2013 Apr;4(2):134-40.
01/04/2013
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenberghe E, Mackinnon S, Chakraverty R.
Br J Haematol. 2013 Mar;160(5):640-8
01/03/2013
Circulating tumor cells as prognostic markers in neuroendocrine tumors
Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T
J Clin Oncol. 2013,31(3):365-72
01/03/2013
A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework. Computer methods and programs in biomedicine
Sarker SJ, Whitehead A, Khan I
Computer methods and programs in biomedicine. 2013,110(3):471-89
01/03/2013
Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I)
Glynne-Jones R, Sebag-Montefiore D, Adams R, Gollins S, Harrison M, Meadows HM, Jitlal M; United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial Working Party.
Cancer. 2013 Feb 15;119(4):748-55
01/02/2013
Capturing data on colostomy formation in anal cancer
Glynne-Jones R, Beare S, Begum R, Kadalayil L
J Clin Oncol. 2013,31(1):164
01/01/2013
Publications in 2012
Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma
Pereira SP, Aithal GP, Ragunath K, Devlin J, Owen F, Meadows H.
Photodiagnosis Photodyn Ther. 2012 Dec;9(4):287-92.
01/12/2012
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C
Lancet. Nov 2012; 13:11: 1161-1170
01/11/2012
Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease
Hardwick N, Ledermann JA, Aitkens E, Chain B
Cancer Immunol Immunother. 2012 Nov;61(11):1929-39
01/11/2012
Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)
Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Van Cutsem E, Lutz MP, Nordlinger B; for the EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG)
Ann Oncol. 2012 Oct;23(10):2619-26.
01/10/2012
Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation
Wong HH, Parkinson C, Ledermann JA, Brenton JD, Merger M, Shaw A, Patterson A, Shafi M, Earl HM.
Gynecol Oncol Case Rep. 2012 Oct 17;3:7-10
01/10/2012
Biomarkers in the development of anti-angiogenic therapies for ovarian cancer
Raja FA, Hook JM, Ledermann JA
Cancer Treat Rev. 2012 Oct;38(6):662-72
01/10/2012
Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies
Jitlal M, Khan I, Lee SM, Hackshaw A
Br J Cancer. 2012 Sep 4;107(6):910-7
01/09/2012
Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma
N Rabin, L Percy, I Khan, J Quinn, S D’Sa, K Yong
Br J Haematol. 2012 Aug;158(4):499-50
01/08/2012
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial
Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson M, Jack A, Hoskin P
Radiother Oncol. 2011 Jul;100(1):86-92
01/07/2012
Attitudes to participation in a lung cancer screening trial: a qualitative study
Patel D, Akporobaro A, Chinyanganya N, Hackshaw A, Seale C, Spiro S, Griffiths C
Thorax. 2012 May;67(5):418-25
01/05/2012
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A
N Engl J Med. 2012 May 3;366(18):1674-85
01/05/2012
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery
Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann JA
Int J Gynecol Cancer. 2012 May;22(4):566-72.
01/05/2012
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U
N Engl J Med. 2012 Apr 12;366(15):1382-92.
01/04/2012
Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo
Mallick U, Harmer C, Hackshaw A, Moss L, IoN Trial Management Group.
Clin Oncol (R Coll Radiol). 2012,24(3):159-61
01/04/2012
High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence
Hoskin P, Rojas A, Lowe G, Bryant L, Ostler P, Hughes R, Milner J, Cladd H
Int J Radiat Oncol Biol Phys. 2012,82(4):1376-84
01/04/2012
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide
Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ
Br J Cancer. 2012 Mar 13;106(6):1153-9
01/03/2012
Family history and women with ovarian cancer: is it asked and does it matter?: An observational study
Lanceley A, Eagle Z, Ogden G, Gessler S, Razvi K, Ledermann JA, Side L
Int J Gynecol Cancer. 2012 Feb;22(2):254-9.
01/02/2012
Review of mammographic screening
Hackshaw A
Special issue of Journal of Medical Screening. Editor of Special Issue. 2012,19(1):5-82.
01/01/2012
Benefits and harms of mammography screening
Hackshaw A
BMJ. 2012,344:d8279
01/01/2012
The benefits and harms of mammographic screening for breast cancer: building the evidence base using service screening programmes
Hackshaw A
J Med Screen. 2012,19:1-2.
01/01/2012
Iodine-stabilized Cu nanoparticle chitosan composite for antibacterial applications
Mallick S, Sharma S, Banerjee M, Ghosh SS, Chattopadhyay A, Paul A
ACS Appl Mater Interfaces. 2012,4(3):1313-23
01/01/2012
Reply to: "Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?"
Meyer T, Kirkwood A, Gillmore R
J Hepatol. 2012,57(1):225-6
01/01/2012
Publications in 2011
A phase 3 trial of bevacizumab in ovarian cancer
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators
N Engl J Med. 2011 Dec 29;365(26):2484-96.
01/12/2011
“Mind the Gap” – The impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I)
Glynne-Jones R, Sebag-Montefiore D, Adams R, McDonald A, Gollins S, James R, Northover JM, Meadows HM, Jitlal M; UKCCCR Anal Cancer Trial Working Party
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1488-94
01/12/2011
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation
Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T
J Hepatol. 2011 Dec; 55(6):1309-16.
01/12/2011
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study
Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister TA, Radford JA, Rohatiner AZ, Linch DC
J Clin Oncol. 2011 Nov 1;29(31):4096-104
01/11/2011
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
Ledermann, JA, Hackshaw, A, Kaye, S B, Jayson, G C, Gabra, IH, McNeish, I, Earl, H, Perren, P, Gore, M, Persic, M, Adams, M, James, L, Temple, G, Merger, M and Rustin, G
J Clin Oncol. 2011 Oct 1;29(28):3798-804.
01/10/2011
Biomarkers in the development of anti-angiogenic therapies for ovarian cancer
Raja FA, Hook JM, Ledermann JA
Cancer Treat Rev. 2012 Oct;38(6):662-72
01/10/2011
Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls
Hackshaw A, Rodeck C, Boniface S
Hum Reprod Update. 2011 Sep-Oct;17(5):589-604.
01/09/2011
Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer
Ledermann JA, Raja FA
Eur J Cancer. 2011 Sep;47 Suppl 3:S104-15
01/09/2011
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
Raja FA, Griffin CL, Qian W, Hirte H, Parmar MK, Swart AM, Ledermann JA
Br J Cancer. 2011 Sep 27;105(7):884-9
01/09/2011
Research and Methods: Interpreting and reporting clinical trials with results of borderline statistical significance
Hackshaw A, Kirkwood A
BMJ. 2011 Jul 4;343:d3340
01/07/2011
Efficacy, safety, and tolerability of sertraline on depressive symptoms in women with comorbid migraine: an open-label study
MacGregor A, Frith A, Hackshaw A
J Clin Psychopharmacol. 2011 Jun;31(3):392-3.
01/06/2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup
Int J Gynecol Cancer. 2011 May;21(4):763-70
01/05/2011
Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference
Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E; participants of 4th Ovarian Cancer Consensus Conference (OCCC); Gynecologic Cancer Intergroup. 2010 Gynecologic Cancer InterGroup (GCIG)
Int J Gynecol Cancer. 2011 May;21(4):750-5
01/05/2011
Long-term benefits of 5 years of tamoxifen: 10 year follow up of a large randomised trial in women aged at least 50 years with early breast cancer
Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, Baum M
J Clin Oncol. 2011 May 1;29(13):1657-63
01/05/2011
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation
Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, Hough R, Morris EC, Fielding A, Chakraverty R, Thomson KJ, Mackinnon S
J Clin Oncol. 2011 Mar 10;29(8):971-8
01/03/2011
Stromal features are predictive of disease mortality in oral cancer patients.
Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, Kalavrezos N, Violette SM, Weinreb PH, Chester KA, Chana J, Marshall JF, Hart IR, Hackshaw AK, Piper K, Thomas GJ
J Pathol. 2011 Mar;223(4):470-81.
01/03/2011
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma
Barrington SF, MacKewn JE, P. Schleyer, P. K. Marsden, N. G. Mikhaeel, W. Qian, P. Mouncey, P. Patrick, B. Popova, P. Johnson, J. Radford & M. J. O’Doherty
Ann Oncol. 2011 Mar;22(3):739-45
01/03/2011
Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%
Mohamedbhai SG, Sibson K, Marafioti T, Kayani I, Lowry L, Goldstone AH, Linch DC, Ardeshna KM
Br J Haematol. 2011 Jan;152(2):175-81
01/01/2011
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H
Lancet. 2011 Jan 1;377(9759):42-51
01/01/2011
Publications in 2010
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J
N Engl J Med. 2010 Apr 8;362(14):1273-81
01/04/2010
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies
Vergote IE, Pujade-Lauraine E,Pignata S, Kristensen GB, Ledermann JA, Casado A, Sehouli J, Mirza M, Fossati R, Marth C. Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee Ate GJ, du Bois A
Int J Gynecol Cancer. 2010 Apr;20(3):476-8.
01/04/2010
Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M
Br J Haematol. 2010 Apr;149(2):237-43.
01/04/2010
Chemotherapy with 5-Fluorouracil, Cisplatin and Streptozocin (FCiSt) for neuroendocrine tumors
Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Buscombe J, Grillo J, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T
Br J Cancer. 2010 Mar 30;102(7):1106-12.
01/03/2010
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al
Br J Cancer. 2010 Mar 30;102(7):1123-8.
01/03/2010
Chemo-radiotherapy for locally advanced head and neck cancer: ten-year follow up of the UK Head and Neck (UKHAN1) trial
Tobias J, Monson K, Gupta N, MacDougall H, Glaholm J, Hutchison I, Kadalayil L, Hackshaw A
Lancet Oncol. 2010 Jan;11(1):66-74
01/01/2010
Publications in 2009
Tobacco and other diseases. In Tobacco: The Public Health Disaster of the Twentieth Century
Hackshaw AK
Second edition Oxford University Press 2009
01/12/2009
Trial design strategies for vascular-targeted therapy of ovarian cancer
Varughese M.A. and Ledermann J.A
Clinical Ovarian Cancer, 2(1): 2-5
01/12/2009
Randomized double-blind placebo-controlled trial of Thalidomide in combination with Gemcetabine and Carboplatin in advanced non-small-cell lung cancer
Lee SM, Rudd R, Woll P, Ottensmeier C, Gilligan D, Price A, Spiro S, Gower N, Jitlal M, Hackshaw A
J Clin Oncol. 2009 Nov 1;27(31):5248-54.
01/11/2009
Luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of breast cancer
Hackshaw A
Expert Opin Pharmacother. 2009 Nov;10(16):2633-9.
01/11/2009
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW.
J Clin Oncol. 2009 Nov 10;27(32):5390-6.
01/11/2009
Circulating Angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis
Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin ME, Meyer T
Endocr Relat Cancer. 2009 Sep;16(3):967-76
01/09/2009
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized double-blind placebo-controlled trial
Lee SM, Woll P, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Alil K, Jitlal M, Hackshaw A
J Natl Cancer Inst. 2009 Aug 5;101(15):1049-57.
01/08/2009
Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy
Maniaci V, Davidson B, Rolles K, Dhillon P, Hackshaw A, Begent R, Meyer T
Eur J Surg Oncol. 2009 Jun;35(6):617-21.
01/06/2009
Assessment of two novel ventilatory surrogates for use in the delivery of gated/tracked radiotherapy for non-small cell lung cancer
Hughes S, McClelland J, Tarte S, Lawrence D, Ahmad S, Hawkes D and Landau D
Radiother Oncol. 2009 Jun;91(3):336-41.
01/06/2009
Positioning pemetrexed in the treatment of ovarian cancer
Ledermann JA, Stebbing J
Eur J Cancer. 2009 May;45(8):1330-2.
01/05/2009
Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO
Sharma R, Cunningham D, Smith P, Robertson G, Dent O and Clarke S.J
BMC Cancer. 2009 May 18;9:153.
01/05/2009
Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma
Kulkarni AA, Kingsbury SR, Tudzarova S, Hong HK, Loddo M, Rashid M, Rodriguez-Acebes S, Prevost AT, Ledermann JA, Stoeber K, and Williams GH
Clin Cancer Res. 2009 Apr 1;15(7):2417-25
01/04/2009
Publications in 2008
Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244
Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW.
Blood, 112 (11), 144
01/11/2008
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2019 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us